Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable Viremia
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Chronic inflammation persists in some people living with human immunodeficiency virus (HIV) during antiretroviral therapy and is associated with premature aging. The glycoprotein 120 (gp120) subunit of HIV-1 envelope sheds and can be detected in plasma, showing immunomodulatory properties even in the absence of detectable viremia. We evaluated whether plasma soluble gp120 (sgp120) and a family of gp120-specific anti-cluster A antibodies, linked to CD4 depletion in vitro, contribute to chronic inflammation, immune dysfunction, and subclinical cardiovascular disease in participants of the Canadian HIV and Aging Cohort Study with undetectable viremia.
METHODS: Cross-sectional assessment of sgp120 and anti-cluster A antibodies was performed in 386 individuals from the cohort. Their association with proinflammatory cytokines and subclinical coronary artery disease was assessed using linear regression models.
RESULTS: High levels of sgp120 and anti-cluster A antibodies were inversely correlated with CD4+ T cell count and CD4/CD8 ratio. The presence of sgp120 was associated with increased levels of interleukin 6. In participants with detectable atherosclerotic plaque and detectable sgp120, anti-cluster A antibodies and their combination with sgp120 levels correlated positively with the total volume of atherosclerotic plaques.
CONCLUSIONS: This study showed that sgp120 may act as a pan toxin causing immune dysfunction and sustained inflammation in a subset of people living with HIV, contributing to the development of premature comorbid conditions.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:229 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 229(2024), 3 vom: 14. März, Seite 763-774 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Benlarbi, Mehdi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti–cluster A antibodies |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 16.03.2024 published: Print UpdateOf: medRxiv. 2023 Aug 16;:. - PMID 37645879 Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad503 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365269751 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365269751 | ||
| 003 | DE-627 | ||
| 005 | 20240316232613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad503 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM365269751 | ||
| 035 | |a (NLM)38035854 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Benlarbi, Mehdi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable Viremia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a UpdateOf: medRxiv. 2023 Aug 16;:. - PMID 37645879 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Chronic inflammation persists in some people living with human immunodeficiency virus (HIV) during antiretroviral therapy and is associated with premature aging. The glycoprotein 120 (gp120) subunit of HIV-1 envelope sheds and can be detected in plasma, showing immunomodulatory properties even in the absence of detectable viremia. We evaluated whether plasma soluble gp120 (sgp120) and a family of gp120-specific anti-cluster A antibodies, linked to CD4 depletion in vitro, contribute to chronic inflammation, immune dysfunction, and subclinical cardiovascular disease in participants of the Canadian HIV and Aging Cohort Study with undetectable viremia | ||
| 520 | |a METHODS: Cross-sectional assessment of sgp120 and anti-cluster A antibodies was performed in 386 individuals from the cohort. Their association with proinflammatory cytokines and subclinical coronary artery disease was assessed using linear regression models | ||
| 520 | |a RESULTS: High levels of sgp120 and anti-cluster A antibodies were inversely correlated with CD4+ T cell count and CD4/CD8 ratio. The presence of sgp120 was associated with increased levels of interleukin 6. In participants with detectable atherosclerotic plaque and detectable sgp120, anti-cluster A antibodies and their combination with sgp120 levels correlated positively with the total volume of atherosclerotic plaques | ||
| 520 | |a CONCLUSIONS: This study showed that sgp120 may act as a pan toxin causing immune dysfunction and sustained inflammation in a subset of people living with HIV, contributing to the development of premature comorbid conditions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV-1 | |
| 650 | 4 | |a anti–cluster A antibodies | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a chronic inflammation | |
| 650 | 4 | |a soluble gp120 | |
| 650 | 7 | |a HIV Antibodies |2 NLM | |
| 650 | 7 | |a Glycoproteins |2 NLM | |
| 650 | 7 | |a HIV Envelope Protein gp120 |2 NLM | |
| 700 | 1 | |a Richard, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Bourassa, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Tolbert, William D |e verfasserin |4 aut | |
| 700 | 1 | |a Chartrand-Lefebvre, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Gendron-Lepage, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Sylla, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a El-Far, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Messier-Peet, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Guertin, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Turcotte, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Fromentin, Rémi |e verfasserin |4 aut | |
| 700 | 1 | |a Verly, Myriam Maude |e verfasserin |4 aut | |
| 700 | 1 | |a Prévost, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Mothes, Walther |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Maldarelli, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Chomont, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Bégin, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Tremblay, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Baril, Jean-Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Trottier, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Trottier, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Duerr, Ralf |e verfasserin |4 aut | |
| 700 | 1 | |a Pazgier, Marzena |e verfasserin |4 aut | |
| 700 | 1 | |a Durand, Madeleine |e verfasserin |4 aut | |
| 700 | 1 | |a Finzi, Andrés |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 229(2024), 3 vom: 14. März, Seite 763-774 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:229 |g year:2024 |g number:3 |g day:14 |g month:03 |g pages:763-774 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad503 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 229 |j 2024 |e 3 |b 14 |c 03 |h 763-774 | ||